Ribociclib Hybrid Lipid–Polymer Nanoparticle Preparation and Characterization for Cancer Treatment

Ribociclib is a newly approved orally administered drug for breast cancer. This study aimed to prepare, characterize, and evaluate hybrid lipid–polymer nanoparticles (PLNs) of ribociclib to enhance its in vitro dissolution rate, pharmacokinetics, and anticancer efficacy. Ribociclib-loaded PLNs were...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Shdefat, Ramadan, Hailat, Mohammad, Alshogran, Osama Y., Abu Dayyih, Wael, Gardouh, Ahmed, Al Meanazel, Osaid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347058/
https://www.ncbi.nlm.nih.gov/pubmed/37447489
http://dx.doi.org/10.3390/polym15132844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347058/
https://www.ncbi.nlm.nih.gov/pubmed/37447489
http://dx.doi.org/10.3390/polym15132844

Ejemplares similares